Sign In
Buy PASG
$4.47
-0.0200 (-0.445%)
At Close: Jul 31, 2026
Passage Bio Welcomes Tom Kassberg to Board of Directors
07:52am, Tuesday, 10'th Sep 2024
PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases
Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
07:00am, Friday, 30'th Aug 2024
PHILADELPHIA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,
Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
07:00am, Thursday, 08'th Aug 2024
Enrolled first FTD-GRN patient in Cohort 2 in upliFT-D trial Plan to present updated safety and biomarker data from Cohort 1 FTD-GRN patients treated with PBFT02 at 14th International Conference on Fr
Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
07:00am, Thursday, 01'st Aug 2024
Granted exclusive, worldwide rights for the development and commercialization of PBGM01 for GM1 gangliosidosis, PBKR03 for Krabbe disease, and PBML04 for metachromatic leukodystrophy to GEMMA Biothera
Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients
07:00am, Tuesday, 16'th Jul 2024
Agency feedback from Type C meeting process supports the company's proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations
Passage Bio (PASG) Loses -22.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:35am, Tuesday, 18'th Jun 2024
The heavy selling pressure might have exhausted for Passage Bio (PASG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analyst
Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference
07:30am, Wednesday, 05'th Jun 2024
PHILADELPHIA, June 05, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,
Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award
08:00am, Tuesday, 21'st May 2024
PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,�
All You Need to Know About Passage Bio (PASG) Rating Upgrade to Buy
01:01pm, Thursday, 16'th May 2024
Passage Bio (PASG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
07:00am, Tuesday, 14'th May 2024
PHILADELPHIA, May 14, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,�
Passage Bio to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
07:00am, Monday, 22'nd Apr 2024
PHILADELPHIA, April 22, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases
Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know
01:01pm, Thursday, 07'th Mar 2024
Does Passage Bio, Inc. (PASG) have what it takes to be a top stock pick for momentum investors? Let's find out.
Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights
07:00am, Monday, 04'th Mar 2024
PHILADELPHIA, March 04, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases
Passage Bio to Participate in Upcoming Investor Conferences
07:00am, Tuesday, 27'th Feb 2024
PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,
7 Analyst-Backed Stocks With Promising 10-Bagger Potential
07:09pm, Thursday, 01'st Feb 2024
Stay on the Internet long enough – and it won't take too long, believe me – and you'll come across voices that blast the virtues of analyst-backed stocks. Ranging anywhere from legitimate concerns
